Eli Lilly and Company EBIT

Eli Lilly and Company (LLY.DE) currently reports a EBIT of $40B as of September 2026. That compares with $23B in the prior-year period — up 71.0% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Eli Lilly and Company's EBIT history and peer comparisons.

Eli Lilly and Company's EBIT increased from $23B to $40B — a 71.0% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eli Lilly and Company's EBIT of $40B is lower than the Healthcare sector average of $130B. That is roughly 70.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eli Lilly and Company reported $40B in EBIT as of September 2026. That compares with $23B in the prior-year period — up 71.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $40B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Eli Lilly and Company, and consider following LLY.DE for alerts when major investors trade the stock.